Status:
COMPLETED
Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic Conjunctivitis
Lead Sponsor:
Bausch & Lomb Incorporated
Conditions:
Allergic Conjunctivitis
Eligibility:
All Genders
10+ years
Phase:
PHASE3
Brief Summary
The primary objective of this study is to investigate the efficacy and safety of bromfenac ophthalmic solution for treatment in subjects with a history of allergic conjunctivitis
Eligibility Criteria
Inclusion
- History of clinically active allergic conjunctivitis
- Agree to return for all required visits
- Agree to avoid disallowed meds
Exclusion
- Known hypersensitivity to bromfenac and salicylates
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
End Date :
August 1 2007
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT00423007
Start Date
November 1 2006
End Date
August 1 2007
Last Update
March 14 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ISTA Pharmaceuticals, Inc.
Irvine, California, United States, 92618